Search research articles
Contact Us
Filters
Showing results (231-240 of 242) with videos related to
Page
of 25
Sort By:
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia
|
August 14, 2025
Prone transpsoas (PTP)-LLIF approach versus standard LLIF in patients undergoing surgical revision following adult spinal deformity correction surgery
Luis D Diaz-Aguilar, Nolan J Brown, Andrew Nguyen, et al.
European Urology
|
September 1, 2021
The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study
Louise Emmett, James Buteau, Nathan Papa, et al.
European Urology Oncology
|
December 7, 2023
Clinical Trial Protocol for PRIMARY2: A Multicentre, Phase 3, Randomised Controlled Trial Investigating the Additive Diagnostic Value of [<sup>68</sup>Ga]Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Negative or Equivocal Multiparametric Magnetic Resonance Imaging for the Diagnosis of Clinically Significant Prostate Cancer
James P Buteau, Daniel Moon, Michael T Fahey, et al.
European Urology
|
April 9, 2026
Prognostic Value of Interim PSMA-PET Total Tumor Volume for Overall Survival Within ENZA-p, A Randomized Phase 2 Trial of Enzalutamide Versus Enzalutamide Plus [<sup>177</sup>Lu] Lu-PSMA-617 (ANZUP1901)
Louise Emmett, Nathan Papa, Oliver Sartor, et al.
Nature Biotechnology
|
June 29, 2026
Retargeted serine integrases for one-step, precise integration of large DNA sequences in human cells
Friedrich Fauser, Sebastian Arangundy-Franklin, Jessica E Davis, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
May 21, 2026
Salvage Radiotherapy Confers an Overall Survival Advantage in Biochemical Recurrence of Prostate Cancer: Evidence from the International PROMISE Registry
Nika Guberina, Madeleine J Karpinski, Maja Guberina, et al.
Radiology
|
April 28, 2026
<sup>177</sup>Lu-PSMA-617 SPECT/CT for Early Prediction of Overall Survival in Participants with Metastatic Castration-Resistant Prostate Cancer
Narjess Ayati, Nathan Papa, Megan Crumbaker, et al.
The Lancet. Oncology
|
June 10, 2026
Effect of [<sup>68</sup>Ga]Ga-PSMA-11 PET-CT in the diagnosis of prostate cancer in men with equivocal or clinically high-risk non-suspicious findings on multiparametric MRI (PRIMARY2): a multicentre, non-inferiority, phase 3, randomised controlled trial
James P Buteau, Daniel Moon, Michael T Fahey, et al.
The Lancet. Oncology
|
April 15, 2024
[<sup>177</sup>Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial
Louise Emmett, Shalini Subramaniam, Megan Crumbaker, et al.
The Lancet. Oncology
|
February 16, 2025
Overall survival and quality of life with [<sup>177</sup>Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial
Louise Emmett, Shalini Subramaniam, Megan Crumbaker, et al.
Page
of 25
Search research articles
Search
Showing results (231-240 of 242) with videos related to
Sort By:
Page
of 25
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia
|
August 14, 2025
Prone transpsoas (PTP)-LLIF approach versus standard LLIF in patients undergoing surgical revision following adult spinal deformity correction surgery
Luis D Diaz-Aguilar, Nolan J Brown, Andrew Nguyen, et al.
European Urology
|
September 1, 2021
The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study
Louise Emmett, James Buteau, Nathan Papa, et al.
European Urology Oncology
|
December 7, 2023
Clinical Trial Protocol for PRIMARY2: A Multicentre, Phase 3, Randomised Controlled Trial Investigating the Additive Diagnostic Value of [<sup>68</sup>Ga]Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Negative or Equivocal Multiparametric Magnetic Resonance Imaging for the Diagnosis of Clinically Significant Prostate Cancer
James P Buteau, Daniel Moon, Michael T Fahey, et al.
European Urology
|
April 9, 2026
Prognostic Value of Interim PSMA-PET Total Tumor Volume for Overall Survival Within ENZA-p, A Randomized Phase 2 Trial of Enzalutamide Versus Enzalutamide Plus [<sup>177</sup>Lu] Lu-PSMA-617 (ANZUP1901)
Louise Emmett, Nathan Papa, Oliver Sartor, et al.
Nature Biotechnology
|
June 29, 2026
Retargeted serine integrases for one-step, precise integration of large DNA sequences in human cells
Friedrich Fauser, Sebastian Arangundy-Franklin, Jessica E Davis, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
May 21, 2026
Salvage Radiotherapy Confers an Overall Survival Advantage in Biochemical Recurrence of Prostate Cancer: Evidence from the International PROMISE Registry
Nika Guberina, Madeleine J Karpinski, Maja Guberina, et al.
Radiology
|
April 28, 2026
<sup>177</sup>Lu-PSMA-617 SPECT/CT for Early Prediction of Overall Survival in Participants with Metastatic Castration-Resistant Prostate Cancer
Narjess Ayati, Nathan Papa, Megan Crumbaker, et al.
The Lancet. Oncology
|
June 10, 2026
Effect of [<sup>68</sup>Ga]Ga-PSMA-11 PET-CT in the diagnosis of prostate cancer in men with equivocal or clinically high-risk non-suspicious findings on multiparametric MRI (PRIMARY2): a multicentre, non-inferiority, phase 3, randomised controlled trial
James P Buteau, Daniel Moon, Michael T Fahey, et al.
The Lancet. Oncology
|
April 15, 2024
[<sup>177</sup>Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial
Louise Emmett, Shalini Subramaniam, Megan Crumbaker, et al.
The Lancet. Oncology
|
February 16, 2025
Overall survival and quality of life with [<sup>177</sup>Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial
Louise Emmett, Shalini Subramaniam, Megan Crumbaker, et al.
Page
of 25